Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03221309 · ClinicalTrials.gov registry record
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
A clinical trial of HCV and PrEP, sponsored by University of Maryland, Baltimore.
- Active
- Registry status
- 198
- Enrollment target
- 2
- Study locations
NCT03221309 is a study of HCV and PrEP that is active but no longer recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 198 participants, above the 174-participant average among 8 other HCV trials with a reported enrollment target (14% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT03221309, a study of HCV and PrEP, is active but no longer recruiting, sponsored by University of Maryland, Baltimore.
- ACTIVE NOT RECRUITING
- Registry status
- 198 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open label, non-randomized, observational pilot study to evaluate a model of care for treatment of hepatitis C in people with ongoing injection drug use. Participants will be treated with direct-acting antivirals (DAA) as per standard of care and will concomittantly be offered pre-exposure prophylaxis for HIV prevention and buprenorphine for treatment of opioid use disorder when clinically indicated.
Conditions Studied
Interventions
- OTHER Evaluate model of care for HCV-infected adults with on-going opioid misuse
Study Locations (2)
District of Columbia
- HIPS - Washington D.C.
Maryland
- University of Maryland Drug Treatment Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2026-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03221309
The ClinicalTrials.gov registry entry for NCT03221309 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 8 other HCV trials with a reported enrollment target (14% higher). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HCV appearing as the primary indexed condition, and to 1 intervention - of which Evaluate model of care for HCV-infected adults with on-going opioid misuse is the first listed.
NCT03221309 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03221309 about?
NCT03221309 is a clinical study titled "Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior". This is an open label, non-randomized, observational pilot study to evaluate a model of care for treatment of hepatitis C in people with ongoing injection drug use. Participants will be treated with direct-acting antivirals (DAA) as per standard of care and will concomittantly be offered pre-exposur...
What is the current status of trial NCT03221309?
This trial is currently active not recruiting. The enrollment target is 198 participants. The study started on 2017-05-01. Estimated completion is 2026-01.
What conditions does trial NCT03221309 study?
This clinical trial studies the following conditions: HCV, PrEP, Buprenorphine.
What interventions are being tested in trial NCT03221309?
The interventions under investigation include: Evaluate model of care for HCV-infected adults with on-going opioid misuse (OTHER).
Who is sponsoring clinical trial NCT03221309?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03221309 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
RECRUITING · NA
-
A Setting Focus Overdose Prevention Intervention
RECRUITING · NA
-
Appalachian Partnership to Reduce Disparities (Aim 2)
RECRUITING · NA
-
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
ACTIVE NOT RECRUITING · NA
-
Integrated HIV Prevention and HCV Care for PWID
ACTIVE NOT RECRUITING · NA
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.